Search

Byline: Our Bureau USV Pvt Ltd, a leading healthcare company, announced that the company recently launched Q rite tablets, containing 200 milligrams (mg) of quinidine sulphate for patients with rare [...]

Byline: Our Bureau The Association of Physicians of India (API), along with global healthcare company Abbott, conducted the first ever 'Angina Awareness Week' in India, from June 19th to June [...]

Sunnyvale-headquartered BioCardia, a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, has announced Centers for Medicare & Medicaid Services (CMS) approval for reimbursement coverage [...]

Glucagon-like peptide-1 receptor agonists (GLP-1s) have gained widespread attention over the past several years. GLP-1s, which includes tirzepatide (Mounjaro, Zepvound), are used to treat patients with type 2 diabetes (T2D) [...]

Women being treated for breast cancer who have a high BMI may be more likely to experience cardiotoxicity during chemotherapy, according to research being presented at the American College of [...]

The numbers are stark: According to the Heart Disease and Stroke Statistics 2021 Update, compiled each year by the American Heart Association (AHA) and the National Institutes of Health, cardiovascular [...]

New data presented from an investigator-sponsored European trial found managing indicated heart failure patients with Abbott's CardioMEMS HF System resulted in a significant improvement in patient-reported quality-of-life scores as early [...]

Varian, a Siemens Healthineers company, announced that the first participant has been treated in the RADIATE-VT clinical trial (NCT 05765175) at Washington University School of Medicine in St. Louis, Missouri. [...]

Occlutech Holding AG (Occlutech), one of the world's leading providers of minimally invasive structural heart disease devices, has announced that the first patient has been enrolled in the FROST-HF study. [...]

Antev Ltd., a late clinical-stage biotech company developing a novel gonadotrophin-releasing hormone (GnRH) antagonist, Teverelix trifluoroacetate (Teverelix), announces that the US Food & Drug Administration (FDA) has provided written guidance [...]

Abbott announced two approvals as part of its growing suite of electrophysiology products in the global market. The company's TactiFlex Ablation Catheter, Sensor Enabled, the world's only ablation catheter with [...]

Byline: Our Bureau Glenmark Pharmaceuticals Ltd. (Glenmark), an innovation-driven, global pharmaceutical company, launched the sacubitril + valsartan tablets in India, for the treatment of heart failure. Marketed under the brand [...]

Cardiovascular Systems, Inc, a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced that the company has initiated the KAIZEN [...]

The incidence rate of infective endocarditis -- a rare but often fatal inflammation of the heart valves -- among patients with cocaine use disorder or opioid use disorder increased from [...]

Novartis announced results from the phase II open-label extension ORION-3 trial, which showed that Leqvio provides effective low-density lipoprotein cholesterol (LDL-C) reduction over a four-year period in patients with either [...]

New findings from a pre-specified analysis of DELIVER phase III trial data show that AstraZeneca's Farxiga (dapagliflozin) improved symptom burden and health-related quality of life in patients with heart failure [...]

* Patients with heart disease and anxiety were randomized to escitalopram, exercise, or placebo for 12 weeks to evaluate the effects on anxiety and biomarkers of heart disease risk. * Escitalopram resulted in greater improvement in anxiety symptoms relative to placebo, while exercise did not result in improvement over placebo on measures of trait anxiety. * There were no significant between-group differences in change in biomarkers of coronary disease., Patients with heart disease who received the antidepressant escitalopram experienced greater improvement in anxiety symptoms compared with placebo, a 12-week randomized trial has found. Patients in the same trial who [...]

Two studies with Bayerós Factor Xa inhibitor rivaroxaban (Xarelto), the Long-Term Open Label Extension (LTOLE) of the COMPASS trial and the XATOA registry, provide complementary evidence of the benefits of [...]

Byline: Our Bureau A first-of-its-kind therapy in India, a cryoablation procedure using specialized balloon catheter systems was recently done on a patient with atrial fibrillation by Dr Balbir Singh and [...]

Cardiovascular Systems, Inc. (CSI), a medical device company, announced the start of enrollment in a first in-human trial of the peripheral everolimus drug-coated balloon (DCB) being developed by Chansu Vascular [...]

In a new study, researchers demonstrated that they can significantly lower cardiovascular risk for patients with severe mental illness (SMI) by using a clinical decision support system that prompts doctors [...]

Byline: Our Bureau Amrita Hospital, Kochi, and scientists from the School of Biotechnology at Amrita Vishwa Vidyapeetham have indicated that a novel intervention for Covid-19 has been explored with nitric [...]

Byline: Our Bureau Sahajanand Medical Technologies (SMT) Limited has announced positive results from Hydra transcatheter aortic heart valve study which was published in JACC (Journal of American College of Cardiology) [...]

Positive phase IIa results from the EPICCURE trial demonstrated that AZD8601 met the primary endpoint of safety and tolerability in patients with heart failure. In the trial, researchers injected mRNA [...]

Abbott announced new, late-breaking data from the global Leadless II IDE study evaluating Abbott's investigational Aveir leadless pacemaker in patients with certain abnormal heart rhythms. The data shows the Aveir [...]

Merck, known as MSD outside the United States and Canada, announced the initiation of VICTOR (VerICiguaT in adults withChrOnicheart failure and Reduced ejection fraction), a pivotal phase 3 randomized, placebo-controlled [...]

Novartis has reached a commercial agreement with the NHS in England as part of collaboration to pioneer a first-of-its-kind population health management approach to address elevated LDL-C in eligible patients [...]

Amgen announced positive data from the HUYGENS phase 3 study showing that Repatha (evolocumab) in addition to optimized statin therapy, in comparison with optimized statin therapy alone, significantly improved features [...]

Pendopharm, a division of Pharmascience Inc., has announced that Health Canada has issued a Notice of Compliance (NOC) approving Myinfla (colchicine 0.5 mg extended-release tablets), a prescription medicine for use [...]

Bayer announced that the Ministry of Health, Labour, and Welfare (MHLW) in Japan has approved soluble guanylate cyclase (sGC) stimulator vericiguat under the brand name Verquvo. Verquvo (vericiguat) 2.5 mg, [...]